Expert consensus on PD-L1 expression testing in esophageal carcinoma in China.
10.3760/cma.j.cn112152-20221129-00792
- Author:
Li Yan XUE
1
;
Yin LI
2
;
Jing HUANG
3
Author Information
1. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
3. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Collective Name:Esophageal Cancer Cooperative Group of Cancer Pathology Committee of China Anti-Cancer Association;Esophageal Cancer Committee of China Anti-Cancer Association;Esophageal Cancer Expert Committee of Chinese Society of Clinical Oncology;Esophageal Disease Group of Thoracic and Cardiovascular Surgery Society of Chinese Medical Association;Esophageal Surgery Expert Committee of Thoracic Surgery Branch of Chinese Medical Doctor Association
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Expert consensus;
PD-L1;
Testing
- MeSH:
Humans;
B7-H1 Antigen/metabolism*;
Immune Checkpoint Inhibitors/therapeutic use*;
Consensus;
Esophageal Neoplasms/drug therapy*;
Immunotherapy/methods*;
Lung Neoplasms/pathology*
- From:
Chinese Journal of Oncology
2023;45(4):291-297
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immunotherapy represented by immune checkpoint inhibitors programmed death 1 (PD-1) has made great progress in the treatment of esophageal cancer and is rewriting the global paradigm for the treatment of esophageal cancer. According to current data, only a small number of patients with esophageal cancer could benefit from immunotherapy. Therefore, it is a challenge to screen the potential beneficiaries of PD-1 inhibitors. Studies have shown that the expression level of programmed death-ligand 1 (PD-L1) in esophageal cancer is closely associated with the efficacy of PD-1 inhibitors, and PD-L1 is the most important predictive biomarker of the efficacy of PD-1 inhibitors. With the clinical application of different PD-1 inhibitors and PD-L1 protein expression detection platforms, clarifying the clinical significance and timing of detection of PD-L1 protein expression in esophageal cancer, and establishing a standardized PD-L1 testing procedure, are of great significance to improve the accuracy of detection and reduce the difference between laboratories, so as to maximize the therapeutic benefits for patients. This consensus was finally reached, based on the combination of literature, expert experience, and internal discussion and voting of committee members, to provide an accurate and reliable evidence for clinicians to make decisions.
